Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Borstnar, Simona; Palacova, Marketa; Łacko, Aleksandra; Timcheva, Constanta; Nili Gal-Yam, Einav; Papazisis, Konstantinos; Beniak, Juraj; Kudela, Pavol; Rubovszky, Gábor

doi:10.2478/raon-2022-0020

Public

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Shared by NobleBlocks on May 17, 2022 • 12:00 AM UTC

Authors:

Simona Borstnar

Marketa Palacova

Aleksandra Łacko

Abstract

Abstract Background The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2− advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) a...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!